Medical Care Research and Review

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

The Diabetes Educator

Click here to browse AJSM online!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tai-Seale, M.
Right arrow Articles by Obenchain, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tai-Seale, M.
Right arrow Articles by Obenchain, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Medical Care Research and Review, Vol. 57, No. 4, 491-512 (2000)
DOI: 10.1177/107755870005700405

Determinants of Antidepressant Treatment Compliance: Implications for Policy

Ming Tai-Seale

Indiana University

Thomas W. Croghan

Eli Lilly and Company and Indiana University

Robert Obenchain

Eli Lilly and Company

Depression is among the most prevalent, devastating, and undertreated disorders in our society. Treatment with antidepressant medications is effective in controlling symptoms, but treatment beyond the point of symptom resolution is necessary to restore functional status and prevent recurrent episodes. An important step in improving compliance is to identify the determinants of antidepressant treatment compliance. A broader motivation for our study is to examine compliance by patients with a chronic but treatable disease. With claims data between 1990 and 1993, this study uses logistic regression analysis to examine the determinants of compliance among 2,012 antidepressant recipients. The results show that initiating treatment with a tricyclic antidepressant reduces the probability of antidepressant treatment compliance. Initiating treatment with a selective serotonin reuptake inhibitor and undergoing family, group, or individual psychotherapy treatments increase the probability of compliance. Case management does not meaningfully affect compliance. Implications for policy and clinical practice are discussed.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Psychiatr. Serv.Home page
T. W. Croghan, M. Schoenbaum, C. D. Sherbourne, and P. Koegel
A Framework to Improve the Quality of Treatment for Depression in Primary Care
Psychiatr Serv, May 1, 2006; 57(5): 623 - 630.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
M. Olfson, S. C. Marcus, M. Tedeschi, and G. J. Wan
Continuity of Antidepressant Treatment for Adults With Depression in the United States
Am J Psychiatry, January 1, 2006; 163(1): 101 - 108.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
M. Olfson, D. Shaffer, S. C. Marcus, and T. Greenberg
Relationship Between Antidepressant Medication Treatment and Suicide in Adolescents
Arch Gen Psychiatry, October 1, 2003; 60(10): 978 - 982.
[Abstract] [Full Text] [PDF]